CYMAT ANNOUNCES ACTIVATION OF ACCELERATED WARRANT EXPIRY DATE
Cymat Technologies (OTCQB: CYMHF) has announced the activation of its warrant expiry date acceleration clause for 11,671,435 common share purchase warrants issued in April 2025. The acceleration was triggered after the company's shares maintained a closing price at or above $0.16 for ten consecutive trading days on the TSX Venture Exchange.
The warrants, which have an exercise price of $0.13 per share, will now expire on August 22, 2025, 45 days from the announcement date. Cymat specializes in manufacturing Stabilized Aluminum Foam (SAF), a unique ultra-light cellular metallic material used in architectural design, military, and automotive applications.
Cymat Technologies (OTCQB: CYMHF) ha annunciato l'attivazione della clausola di accelerazione della scadenza dei warrant per 11.671.435 warrant di acquisto azioni ordinarie emessi ad aprile 2025. L'accelerazione è stata attivata dopo che le azioni della società hanno mantenuto un prezzo di chiusura pari o superiore a 0,16 $ per dieci giorni di negoziazione consecutivi sulla TSX Venture Exchange.
I warrant, con un prezzo di esercizio di 0,13 $ per azione, scadranno ora il 22 agosto 2025, 45 giorni dalla data dell'annuncio. Cymat è specializzata nella produzione di Schiuma di Alluminio Stabilizzata (SAF), un materiale metallico cellulare ultra-leggero unico, utilizzato nel design architettonico, militare e automobilistico.
Cymat Technologies (OTCQB: CYMHF) ha anunciado la activación de la cláusula de aceleración de la fecha de vencimiento de sus 11.671.435 warrants para la compra de acciones comunes emitidos en abril de 2025. La aceleración se activó después de que las acciones de la empresa mantuvieran un precio de cierre igual o superior a
Los warrants, con un precio de ejercicio de 0,13 $ por acción, ahora expirarán el 22 de agosto de 2025, 45 días desde la fecha del anuncio. Cymat se especializa en la fabricación de Espuma de Aluminio Estabilizada (SAF), un material metálico celular ultra ligero único utilizado en diseño arquitectónico, aplicaciones militares y automotrices.
Cymat Technologies (OTCQB: CYMHF)는 2025년 4월에 발행된 11,671,435개의 보통주 매수 워런트의 만기일 가속 조항을 발동했다고 발표했습니다. 이 가속은 회사 주식이 TSX 벤처 거래소에서 10거래일 연속으로 종가가 0.16달러 이상을 유지한 후 발동되었습니다.
행사가격이 주당 0.13달러인 이 워런트는 이제 발표일로부터 45일 후인 2025년 8월 22일에 만료됩니다. Cymat은 건축 디자인, 군사 및 자동차 분야에 사용되는 독특한 초경량 금속성 셀룰러 소재인 안정화 알루미늄 폼(SAF) 제조를 전문으로 합니다.
Cymat Technologies (OTCQB : CYMHF) a annoncé l'activation de la clause d'accélération de la date d'expiration de ses 11 671 435 bons de souscription d'actions ordinaires émis en avril 2025. L'accélération a été déclenchée après que les actions de la société ont maintenu un cours de clôture égal ou supérieur à 0,16 $ pendant dix jours de bourse consécutifs sur le TSX Venture Exchange.
Les bons, dont le prix d'exercice est de 0,13 $ par action, expireront désormais le 22 août 2025, soit 45 jours après la date de l'annonce. Cymat est spécialisée dans la fabrication de mousse d'aluminium stabilisée (SAF), un matériau métallique cellulaire ultra-léger unique utilisé dans la conception architecturale, les applications militaires et automobiles.
Cymat Technologies (OTCQB: CYMHF) hat die Aktivierung der Beschleunigungsklausel für das Verfallsdatum von 11.671.435 Stammaktien-Kaufoptionsscheinen angekündigt, die im April 2025 ausgegeben wurden. Die Beschleunigung wurde ausgelöst, nachdem die Aktien des Unternehmens an zehn aufeinanderfolgenden Handelstagen an der TSX Venture Exchange einen Schlusskurs von mindestens 0,16 $ erreicht hatten.
Die Optionsscheine, mit einem Ausübungspreis von 0,13 $ pro Aktie, laufen nun am 22. August 2025 ab, 45 Tage nach dem Bekanntgabedatum. Cymat ist auf die Herstellung von Stabilisiertem Aluminium-Schaum (SAF) spezialisiert, einem einzigartigen, ultraleichten zellulären Metallmaterial, das in der Architektur, im Militär und in der Automobilindustrie eingesetzt wird.
- Warrant exercise price of $0.13 is below current trading price of $0.16+, indicating potential exercise proceeds
- Stock price performance triggered acceleration clause by maintaining $0.16+ for 10 consecutive days
- Potential capital injection if warrant holders exercise before expiration
- Accelerated warrant expiration may pressure warrant holders to make decisions sooner than expected
- Potential share dilution if all warrants are exercised
Cymat's common shares have had a closing price at or above
About Cymat Technologies Ltd.
Cymat Technologies Ltd. has the global rights, through patents and established know-how, to manufacture and sell Stabilized Aluminum Foam ("SAF"), a unique, ultra-light, cellular metallic material. The proprietary production process entails the injection of gases through a molten bath of alloyed aluminum infused with ceramic particles. The result is an advanced, lightweight, recyclable material that exhibits unique characteristics including customizable density and dimensions; mechanical energy absorption; thermal and acoustic insulation; and time, temperature and strain-rate insensitivity. A key benefit of this continuous foam production process is its scalability and resultant low cost of production. SAF is used in such industries as architectural design, military and automotive. Cymat markets its architectural SAF under the AlusionTM brand and its automotive and military SAF under the SmartMetalTM brand. For further information, please visit our website www.cymat.com
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Certain material assumptions regarding such forward-looking statements may be discussed in this news release and the Company's annual and quarterly management's discussion and analysis filed at www.sedar.com. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cymat-announces-activation-of-accelerated-warrant-expiry-date-302501204.html
SOURCE Cymat Technologies Ltd.
FAQ
What is the new expiry date for Cymat Technologies (CYMHF) warrants?
How many warrants are affected by CYMHF's accelerated expiry date?
What is the exercise price for Cymat Technologies warrants?
What triggered the warrant acceleration clause for CYMHF?
What does Cymat Technologies (CYMHF) manufacture?
